128 related articles for article (PubMed ID: 29577875)
1. Characterization of antibody-C1q interactions by Biolayer Interferometry.
Zhou W; Lin S; Chen R; Liu J; Li Y
Anal Biochem; 2018 May; 549():143-148. PubMed ID: 29577875
[TBL] [Abstract][Full Text] [Related]
2. Regulation of antibody-mediated complement-dependent cytotoxicity by modulating the intrinsic affinity and binding valency of IgG for target antigen.
Wang B; Yang C; Jin X; Du Q; Wu H; Dall'Acqua W; Mazor Y
MAbs; 2020; 12(1):1690959. PubMed ID: 31829766
[TBL] [Abstract][Full Text] [Related]
3. IgG4 antibodies from patients with asymptomatic bancroftian filariasis inhibit the binding of IgG1 and IgG2 to C1q in a Fc-Fc-dependent mechanism.
Prodjinotho UF; Hoerauf A; Adjobimey T
Parasitol Res; 2019 Oct; 118(10):2957-2968. PubMed ID: 31485865
[TBL] [Abstract][Full Text] [Related]
4. Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody binding.
Kline JB; Fernando S; Ross EN; Grasso L; Nicolaides NC
Eur J Immunol; 2018 Nov; 48(11):1872-1882. PubMed ID: 30144039
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal Antibodies against Epidermal Growth Factor Receptor Acquire an Ability To Kill Tumor Cells through Complement Activation by Mutations That Selectively Facilitate the Hexamerization of IgG on Opsonized Cells.
Tammen A; Derer S; Schwanbeck R; Rösner T; Kretschmer A; Beurskens FJ; Schuurman J; Parren PW; Valerius T
J Immunol; 2017 Feb; 198(4):1585-1594. PubMed ID: 28062698
[TBL] [Abstract][Full Text] [Related]
6. Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity.
Peschke B; Keller CW; Weber P; Quast I; Lünemann JD
Front Immunol; 2017; 8():646. PubMed ID: 28634480
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the C1q-Binding Ability and the IgG1-4 Subclass Profile of Preformed Anti-HLA Antibodies by Solid-Phase Assays.
Navas A; Molina J; Agüera ML; Guler I; Jurado A; Rodríguez-Benot A; Alonso C; Solana R
Front Immunol; 2019; 10():1712. PubMed ID: 31428086
[TBL] [Abstract][Full Text] [Related]
8. Molecular Basis of Assembly and Activation of Complement Component C1 in Complex with Immunoglobulin G1 and Antigen.
Wang G; de Jong RN; van den Bremer ET; Beurskens FJ; Labrijn AF; Ugurlar D; Gros P; Schuurman J; Parren PW; Heck AJ
Mol Cell; 2016 Jul; 63(1):135-45. PubMed ID: 27320199
[TBL] [Abstract][Full Text] [Related]
9. Effects of weak/non-complement-binding HLA antibodies on C1q-binding.
Hönger G; Amico P; Arnold ML; Spriewald BM; Schaub S
HLA; 2017 Aug; 90(2):88-94. PubMed ID: 28585289
[TBL] [Abstract][Full Text] [Related]
10. The Proteolytic Cleavage of Therapeutic Monoclonal Antibody Hinge Region: More Than a Matter of Subclass.
Deveuve Q; Lajoie L; Barrault B; Thibault G
Front Immunol; 2020; 11():168. PubMed ID: 32117299
[TBL] [Abstract][Full Text] [Related]
11. Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.
Quast I; Keller CW; Maurer MA; Giddens JP; Tackenberg B; Wang LX; Münz C; Nimmerjahn F; Dalakas MC; Lünemann JD
J Clin Invest; 2015 Nov; 125(11):4160-70. PubMed ID: 26436649
[TBL] [Abstract][Full Text] [Related]
12. Potential of Murine IgG1 and Human IgG4 to Inhibit the Classical Complement and Fcγ Receptor Activation Pathways.
Lilienthal GM; Rahmöller J; Petry J; Bartsch YC; Leliavski A; Ehlers M
Front Immunol; 2018; 9():958. PubMed ID: 29867943
[TBL] [Abstract][Full Text] [Related]
13. IgG subclass specificity to C1q determined by surface plasmon resonance using Protein L capture technique.
Patel R; Neill A; Liu H; Andrien B
Anal Biochem; 2015 Jun; 479():15-7. PubMed ID: 25797348
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation.
Russell MW; Reinholdt J; Kilian M
Eur J Immunol; 1989 Dec; 19(12):2243-9. PubMed ID: 2606139
[TBL] [Abstract][Full Text] [Related]
15. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
16. The binding site for C1q on IgG.
Duncan AR; Winter G
Nature; 1988 Apr; 332(6166):738-40. PubMed ID: 3258649
[TBL] [Abstract][Full Text] [Related]
17. Novel C1q assay reveals a clinically relevant subset of human leukocyte antigen antibodies independent of immunoglobulin G strength on single antigen beads.
Chen G; Sequeira F; Tyan DB
Hum Immunol; 2011 Oct; 72(10):849-58. PubMed ID: 21791230
[TBL] [Abstract][Full Text] [Related]
18. Binding of the human complement subcomponent C1q to hybrid mouse monoclonal antibodies.
Koolwijk P; Boot JH; Griep R; Bast BJ
Mol Immunol; 1991 Jun; 28(6):567-76. PubMed ID: 1861677
[TBL] [Abstract][Full Text] [Related]
19. IgG Fc domains that bind C1q but not effector Fcγ receptors delineate the importance of complement-mediated effector functions.
Lee CH; Romain G; Yan W; Watanabe M; Charab W; Todorova B; Lee J; Triplett K; Donkor M; Lungu OI; Lux A; Marshall N; Lindorfer MA; Goff OR; Balbino B; Kang TH; Tanno H; Delidakis G; Alford C; Taylor RP; Nimmerjahn F; Varadarajan N; Bruhns P; Zhang YJ; Georgiou G
Nat Immunol; 2017 Aug; 18(8):889-898. PubMed ID: 28604720
[TBL] [Abstract][Full Text] [Related]
20. Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation.
van den Bremer ET; Beurskens FJ; Voorhorst M; Engelberts PJ; de Jong RN; van der Boom BG; Cook EM; Lindorfer MA; Taylor RP; van Berkel PH; Parren PW
MAbs; 2015; 7(4):672-80. PubMed ID: 26037225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
